Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H1 2017’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome)

– The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neuromyelitis Optica (Devic’s Syndrome) therapeutics and enlists all their major and minor projects

– The report assesses Neuromyelitis Optica (Devic’s Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

Alexion Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Biogen Inc

Bionure Farma SL

Chugai Pharmaceutical Co Ltd

Clene Nanomedicine Inc

HanAll Biopharma Co Ltd

Karus Therapeutics Ltd

LFB SA

Marathon Pharmaceuticals LLC

MedImmune LLC

Opexa Therapeutics Inc

Shire Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuromyelitis Optica (Devic’s Syndrome) - Overview

Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development

2-BBB Medicines BV

Alexion Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Biogen Inc

Bionure Farma SL

Chugai Pharmaceutical Co Ltd

Clene Nanomedicine Inc

HanAll Biopharma Co Ltd

Karus Therapeutics Ltd

LFB SA

Marathon Pharmaceuticals LLC

MedImmune LLC

Opexa Therapeutics Inc

Shire Plc

Neuromyelitis Optica (Devic’s Syndrome) - Drug Profiles

2B-3201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANV-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APL-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BN-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cladribine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNMAU-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-15107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inebilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KA-1463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPX-212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SA-237 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Neuromyelitis Optica - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ublituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects

Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones

Featured News & Press Releases

Sep 16, 2016: TG Therapeutics Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Aug 31, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder

Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)

Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program

Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol

May 08, 2015: Initiation Of Phase I Clinical Program

Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting

Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned

Feb 25, 2015: HanAll BioPharma Receives a Grant for HL161 Auto-Immune Project from Korean Drug Development Fund

Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica

Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program

Aug 27, 2014: Clene Files Investigational New Drug Application With FDA

Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis

Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by 2-BBB Medicines BV, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Alexion Pharmaceuticals Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Biogen Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Bionure Farma SL, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Clene Nanomedicine Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Karus Therapeutics Ltd, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by LFB SA, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by MedImmune LLC, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Opexa Therapeutics Inc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Pipeline by Shire Plc, H1 2017

Neuromyelitis Optica (Devic’s Syndrome) – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports